Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in oesophageal cancer (OC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).
Session type: Parallel sessions
Cancer Oesophagus Gefitinib(COG) trial randomised 450 patients(pts) with advanced OC progressing after chemotherapy to gefitinib(G) or placebo(P). Improved disease control rates(DCR), patient reported outcomes, and progression free survival(PFS) were seen with G-indicative of rapid and durable responses that were observed in a subgroup. We hypothesised that EGFR CNG in OCs would identify the subgroup responsive to G.